Table 1 |
|||
|
Spontaneous models of Sjögren's syndrome |
|||
|
Strain/modificationa |
SS-like disease manifestationsb |
Remarksb |
Reference |
|
|
|||
|
(NZB/NZW)F1 |
SG and LG infl. |
SLE-like disease |
[19] |
|
MRL |
SG and LG infl. |
SLE-like disease |
[29] |
|
lpr |
↑ SG and LG infl. |
lpr exacerbates the MRL disease phenotype |
[30] |
|
NFS/sld |
None |
Aberrant proteolysis of α-fodrin |
[33] |
|
3d-Tx |
SG and LG infl. |
Inflammatory lesions in multiple organs |
[34] |
|
IQI/Jic |
SG and LG infl. |
Inflammatory lesions in multiple organs |
[37] |
|
NOD |
SG and LG infl., ↓ SG and LG function |
T1D, multiple immune system-related alterations |
[12] |
|
H2b |
Similar to original NOD strain |
No T1D |
[42] |
|
C57BL/6 |
May develop SG infl. at an old age |
Widely used recipient strain |
|
|
NOD-Aec1Aec2 |
SG and LG infl., ↓ SG and LG function |
Increased applicability compared with NOD mice |
[41] |
|
Il2-/- |
SG and LG infl., ↓ SG function |
Generalized lymphoproliferative disease |
[91] |
|
Il2Rα-/- |
SG and LG infl., ↓ SG function |
Generalized lymphoproliferative disease |
[91] |
|
Foxp3-/- |
None |
More susceptible to SS-like disease |
[94] |
|
Il10 Tg |
SG and LG infl., ↓ SG and LG function |
↑ apoptosis in the SG |
[95] |
|
Il14α Tg |
SG infl., ↓ SG function |
High incidence of CD5+ lymphoma, nephritis |
[101] |
|
Baff Tg |
SG and LG infl., ↓ SG function |
MZ B-cell dominated infl., SLE-like disease |
[106] |
|
Tgfβ1-/- |
SG and LG infl., ↓ SG function |
Poor viability, mixed inflammatory cell response |
[112] |
|
Tgfβ1 Tg |
↓ SG function |
Impaired SG architecture, SG tissue fibrosis |
[113] |
|
Thbs1-/- |
LG infl., anti-Ro and anti-La |
Detailed assessment of the eye component |
[116] |
|
Ar-/- |
SG infl. |
Estrogen-dependent disease |
[119] |
|
RbAp48 Tg |
SG and LG infl., ↓ SG function, anti-Ro and anti-La |
Assessment of the inflammatory milieu in the SG |
[122] |
|
Id3-/- |
SG and LG infl., ↓ SG function, anti-Ro and anti-La |
Exocrine gland dysfunction precedes SG and LG infl. |
[125] |
|
Id3-/-;LckCre |
SG and LG infl., ↓ SG function, anti-Ro and anti-La |
T-cell lineage specific deletion of Id3 |
[126] |
|
r1ΔT/r2n |
SG and LG infl., anti-Ro |
↓ Tregs, inflammatory lesions in multiple organs |
[130] |
|
IκBαM/M |
SG and LG infl., anti-Ro and anti-La |
Defective feedback regulation of NF-κB |
[133] |
|
C57BL/10 |
May develop SG infl. at an old age |
C57BL/6 and C57BL/10 diverged prior to 1937 |
|
|
NOD-Nss1/Idd5 |
SG infl. |
SG function has not been assessed |
[82] |
|
SJL |
SG and LG infl., anti-Ro and anti-La |
Susceptible to multiple autoimmune diseases |
[98] |
|
Il12 Tg |
↑ SG and LG infl., ↓ SG function, ↑ anti-Ro and anti-La |
IL-12 exacerbates the SJL disease phenotype |
[98] |
|
BALB/c |
None |
Often used as control strain |
|
|
Act1-/- |
SG and LG infl., anti-Ro and anti-La |
MZ B-cell dominated infl., SLE-like disease |
[115] |
|
|
|||
|
Selection of murine strains in which Sjögren's syndrome (SS)-like disease manifestations develop spontaneously. ↑, increased; ↓, decreased; Ar, aromatase; 3d-Tz, 3 days after birth thymectomy; infl., inflammation; LG, lacrimal gland; MZ, marginal zone; NOD, nonobese diabetic mice; SG, salivary gland; SLE, systemic lupus erythematosus; T1D, type 1 diabetes; Tg, transgenic; Treg, regulatory T cell. aSpecific modification of the original strain. bFor modified strains, listings refer to relative changes compared with the original, not indented, strain listed above. |
|||
|
Delaleu et al. Arthritis Research & Therapy 2011 13:217 doi:10.1186/ar3313 |
|||